Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatment.
Zorn
Kristin K
KK
Gynecologic Cancer Program, Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, USA.
D000465:Algorithms; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017239:Paclitaxel / Q000008:administration & dosage; D018579:Patient Selection; D011064:Poly Adenosine Diphosphate Ribose / Q000037:antagonists & inhibitors; D011506:Proteins / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011506:Proteins; C024857:poly(ADP)-ribosylated proteins; D011064:Poly Adenosine Diphosphate Ribose; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel